Back |

MPI Research is proud to participate in the 44th annual meeting of the Society of Toxicology March 6-10, 2005 in New Orleans, LA. In recognition of the opportunity for continuing education that the SOT provides its members, we are pleased to provide three stimulating breakfast discussions during this year’s meeting. MPI Research is honored to have three leading experts in their fields offer valuable insight and expertise on topics that are critical issues in today’s efforts to bring safe and effective therapeutics and medical devices to the marketplace.

Monday, March 7th from 7-8 a.m. at the Hilton Riverside Grand Salon 13/16, Craig January, M.D. will chair a stimulating discussion on the clinical issue of drug-induced QT prolongation. Dr. January, a pioneer in the field of cell-drug ion channel interactions, is recognized as a global leader in this area of research. Recent headlines regarding market withdrawal of leading drugs illustrate the importance of early screening of drug candidates for this phenomenon. Dr. January is a Professor of Medicine and Physiology at the University of Wisconsin. As a clinician-scientist, he examines the molecular basis for the interactions of pharmaceuticals with the hERG potassium channel.

Tuesday, March 8th from 7-8 a.m. at the Hilton Riverside Grand Salon 3/6, M.J. Waxdal, Ph.D. will present his thoughts on the use of flow cytometry in the preclinical testing of both large and small molecules. New drug candidates can have significant impact on the immune system; Dr. Waxdal will present a thought provoking perspective on the use of flow cytometry in the evaluation of new therapeutics in both human and animal models. Dr. Waxdal is the Founder and President of FAST Systems, a Licensed Clinical Reference Laboratory specializing in the application of immunological and flow cytometry procedures to biological, biotech and medical entities. With 3+ decades of experience, Dr. Waxdal is internationally recognized for his work in this field.

Wednesday, March 9th from 7-8 a.m. at the Hilton Riverside Grand Salon 3/6, J. Paul Shea, Ph.D. will outline the use of exciting imaging technologies, such as Positron Emission Tomography (PET), CT and MRI in the support of drug discovery and development. These technologies, important tools in the clinical arena, offer important advances in the preclinical development of new therapies. Dr. Shea will share his perspective on the potential and current preclinical uses of these imaging systems. With extensive experience in academia and the private sector, Dr. Shea is a leading expert in drug development and molecular imaging. His company, Luminare Molecular, LLC, provides molecular imaging services to the pharmaceutical and biotech industries. Dr. Shea will also be demonstrating daily the use of PET in animal models during the ToxExpo in the MPI Research booth, #415.

Dr. James Laveglia, Executive Vice President and Director of Research for MPI Research, commented, “Last year we hosted our first breakfast seminar with Dr. January, which was very well received and attended. This year we are pleased to provide three seminars and expand the topics to include immunology and molecular imaging evaluations in preclinical programs. Please join us each day for what we know will be very informative sessions on these important topics.”

Home | News